Potaba-Glenwood

Quick links

Choose a section

Quick links to important sections

Advertisements

Potaba-Glenwood

Advertisements
Advertisements

Overview of Potaba-Glenwood

Property Description
Active Ingredient Potassium para-aminobenzoate (K-PABA)
Pharmacological Class Antifibrosis agent
Dosage Forms Tablets, Capsules, Powder for Oral Solution
Route of Administration Oral
Origin/Type Synthetic derivative, Single-ingredient

What is Potaba-Glenwood and What is its Composition?

Potaba-Glenwood is a prescription medication whose active ingredient is Potassium para-aminobenzoate (K-PABA), which is the monopotassium salt of Aminobenzoic acid (PABA). This substance is an organic aromatic moiety, chemically defined as C7H6KNO2. While its parent compound, Aminobenzoic acid, is structurally related to the Vitamin B complex and naturally occurs in certain contexts, the pharmaceutical entity is a specific synthetic salt designed for internal therapeutic use, classifying it as a single-ingredient product.

The Pharmacological Classification and Forms

The medication's primary pharmacological designation is as an Antifibrosis agent, a classification for its specific activity against the progression of fibrous tissue. Under the Anatomical Therapeutic Chemical (ATC) classification system, Potassium para-aminobenzoate is grouped under Other dermatological preparations (ATC code D11AX23). The compound is utilized for its antifibrotic properties. Potaba-Glenwood is intended for oral administration and is available in various dosage forms, including tablets or capsules, and as powder sachets, which are designed to be dissolved for an oral solution.

General Purpose of an Antifibrosis Agent

The overall purpose of this antifibrosis agent is to interrupt the pathological process of fibrosis, where the body excessively deposits collagen and other structural materials, leading to the hardening and tightening of tissues. Its function is based on physiological actions such as increasing oxygen uptake at the tissue level, which is intended to aid in tissue softening. The mechanism is associated with the inhibition of fibroblast proliferation and collagen production. By targeting the restrictive nature of these tissues, the medication serves to improve the structural pliability and functional integrity of the affected areas, such as in instances of dermal hardening.

Advertisements

What side effects are possible with Potaba-Glenwood?

Possible Side Effects and Safety Information

The safety profile for Potaba-Glenwood (Potassium para-aminobenzoate) includes potential for serious adverse events and requires patient monitoring. Side effects are classified by frequency, with Common effects (up to 1 in 10 people) primarily involving the Gastrointestinal system, such as nausea, vomiting, loss of appetite, and diarrhea, along with generalized symptoms like fever and chills.

Serious and Clinically Significant Adverse Reactions

Severe cutaneous adverse reactions (SCARs), including DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) or drug hypersensitivity syndrome, are potential but Not known (frequency cannot be estimated) or Very rare risks, which can be life-threatening and involve systemic organ damage. Other serious risks include Hepatobiliary disorders (hepatitis, drug-induced liver injury) and Metabolic disturbances, specifically hypoglycaemia (low blood sugar), which can cause confusion, shaking, and anxiety, and hyperkalaemia (high blood potassium levels).

Safety Restrictions and Monitoring

Contraindications for use include a history of severe skin reactions to the drug, kidney disease, pre-existing hyperkalaemia, or concomitant use with sulfonamide medicines. Due to the risk of severe reactions, liver function tests must be monitored regularly (at least every 4 weeks initially). Serum potassium levels must also be monitored, particularly in at-risk patients (e.g., those with diabetes or heart conditions) or in cases of reduced food intake, which increases the risk of hypoglycaemia. Immediate discontinuation of the medicine is required if signs of hypersensitivity, severe rash, or liver disorder symptoms are observed.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The FDA New Drug Application (NDA) for Potaba-Glenwood (Potassium Aminobenzoate) was ultimately withdrawn because the drug was determined, through the Drug Efficacy Study Implementation (DESI) process, to lack substantial evidence of effectiveness for its intended uses. Consequently, the official government regulatory records that address this final regulatory status do not contain specific, documented information concerning overdose presentations, symptoms, or required emergency procedures for this product.

However, in the context of the active ingredient Potassium Aminobenzoate, the general risk of hypoglycemia (low blood sugar) has been identified, and this condition may require urgent medical attention. Symptoms of severe hypoglycemia can include profound confusion, loss of consciousness, or an altered mental state. Additionally, due to its potassium content, cautious use is advised in individuals with kidney disease or other conditions that may increase blood potassium levels.

Emergency Actions and Medical Help

Classification Detail (Based on Safety/Toxicity Data)
Key Overdose-Associated Risk Hypoglycemia (low blood sugar)
Symptom Clusters Symptoms of low blood sugar, including anxiety, confusion, cold sweats, fast heartbeat, or severe weakness.
When to Seek Help Seek immediate medical attention if symptoms of severe hypoglycemia appear, such as passing out or having a seizure, or if any suspected overdose is followed by acute, severe reactions like a widespread rash, high fever, or signs of liver disorder.

Should there be any concern regarding excessive consumption, or if serious adverse effects occur, contact a poison control center or seek emergency medical care immediately.

Advertisements

Therapeutic Uses of Potaba-Glenwood

What Potaba-Glenwood Treats: Main Uses and Benefits

The primary purpose of Potaba-Glenwood (Potassium para-aminobenzoate) is to offer symptomatic relief and supportive therapeutic benefit within specific domains characterized by abnormal tissue changes and related discomfort. The medication is utilized within the symptomatic management of Peyronie's disease and scleroderma. It is used for managing the often distressing manifestations that can intensify over time and interfere with daily function.


Supportive Management in Fibrotic Conditions

Potaba-Glenwood is commonly used across conditions presenting with acute episodes of tissue rigidity and inflammation, such as Peyronie's disease (penile fibrotic plaque) and certain forms of scleroderma (morphea). It is applied when appropriate in contexts where additional support for symptom management is needed due to the thickening of connective tissues. This approach may assist with maintaining a sense of stability when symptoms are more noticeable.

“Provides supportive relief when symptoms interfere with routine activities.”

Addressing Acute Symptomatic Discomfort

The medication is intended for managing symptoms that may appear suddenly or intensify over time, such as pain or stiffness associated with active inflammation in fibrotic tissues. It is often used during phases when symptoms become more noticeable and create noticeable functional strain. This provides symptomatic support that supports general well-being during symptomatic phases.

Quick Fact: Relief for Symptoms related to Physical Discomfort

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Potaba-Glenwood — Official Regulatory Information

Eligibility Scope Classification Populations
Populations for whom use is allowed (as stated in label) Adults being treated for Peyronie's disease and scleroderma
Populations for whom use is not recommended (if applicable) Children and adolescents (age 0 to 18 years); Pregnant or Breastfeeding individuals
Populations for whom use is contraindicated Patients with known Hypersensitivity, Kidney Disease, Severe Liver Damage, Hyperkalaemia, or a history of SCARs

Age-Related Eligibility Rules Use is not recommended for children and adolescents (under 18 years) because the medicine's safety and effectiveness have not been established in this age group. Older adults may require special consideration due to increased sensitivity, particularly to the risk of hypoglycemia.

Condition-Specific Eligibility Rules Potaba-Glenwood is contraindicated in patients with renal insufficiency or severe liver damage. It is also prohibited for patients with a high potassium level (hyperkalaemia). Caution is advised for those with Diabetes Mellitus or conditions that increase the risk of elevated blood potassium.

Eligibility-Related Restrictions The medicine is contraindicated for use with Sulfonamide Antibiotics due to the risk of drug inactivation. Treatment must be interrupted during periods of low food intake to avoid the possible development of hypoglycemia.

Connection to the overall eligibility profile Regulatory documents strictly define eligibility based on absolute contraindications related to organ function and metabolic status. Use is restricted or not recommended for populations where safety is not established, such as in pediatric, pregnant, and breastfeeding groups.

Advertisements

What should I know about interactions with other medicines?

Potaba-Glenwood has formally documented interaction patterns with other medicinal products and substances, as described in authoritative government regulatory documents.

Contraindicated Combinations and Conditions

Co-administration with Sulphonamides (Sulfa drugs) is officially contraindicated because Potassium para-aminobenzoate has been shown to inactivate the sulphonamide medicinal product. Furthermore, the medicine is contraindicated in individuals with renal insufficiency where the glomerular filtration rate (GFR) is less than 45 ml/min. This specific restriction is mandated due to the drug's potassium content and the significant risk of hyperkalaemia (elevated potassium levels) when renal clearance is impaired.

Exposure-Altering and Pharmacodynamic Interactions

Certain drug combinations may alter systemic exposure or result in additive pharmacodynamic effects. When co-administered with Methotrexate, the plasma levels of Methotrexate may be increased due to documented protein-binding displacement. Due to the inherent potassium content of the drug, caution is required with other potassium-elevating medicinal products, including Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs), and potassium-sparing diuretics, as this leads to an additive risk of hyperkalaemia. This potassium load can also result in a reduced effect of concomitant cardiac glycosides.

Substance and Timing Restrictions

Official labeling includes specific administration constraints. Alcohol consumption must be avoided because of a documented risk of additive effects that may lower blood sugar. Additionally, treatment must be interrupted during periods of low food intake, such as fasting or anorexia, to mitigate the potential development of hypoglycaemia.

Advertisements

Mechanism of Action

How Potaba-Glenwood Works

Potaba-Glenwood, containing aminobenzoate potassium, exerts its action through two primary mechanistic domains that regulate molecular pathways associated with connective tissue remodeling.

Modulation of Fibroblast Activity and Collagen Deposition

This mechanism involves the inhibition of fibroblast proliferation, the cell type responsible for producing the structural components of connective tissue. By modulating the synthetic output of these cells, the compound influences the deposition rate and ultimate organization of collagen and other extracellular matrix components. The resulting reduction in fibroblast activity influences the structural and mechanical properties of the targeted tissue.


Regulation of Tissue Biochemistry and Mediator Catabolism

Potaba-Glenwood influences local tissue biochemistry by increasing oxygen uptake in the affected microenvironment. This elevated oxygenation is correlated with an increase in monoamine oxidase (MAO) enzyme activity. This enhanced enzymatic function facilitates the catabolism of specific vasoactive and profibrotic mediators, thereby modulating their localized concentrations and influencing the dynamics of extracellular matrix accumulation.

Advertisements

Dosage and Administration Information

How to Use Potaba-Glenwood: Administration Guidelines

Potaba-Glenwood (Potassium para-aminobenzoate) is administered orally and is available in formulations such as 500 mg tablets, capsules, and 3 gram sachets of powder for oral solution. The administration protocol is established to provide a standardized approach for use in clinical practice.


Administration Protocol

Instruction Detail
Route of Administration Oral
Dosing Schedule The standard adult total daily dose is 12 grams, which is divided and taken in four separate 3-gram doses daily.
Timing in Relation to Meals Dosing must occur with food (i.e., immediately following a meal or with a small snack).
Preparation Requirements The powder must be completely dissolved in a full glass of water or fruit juice prior to consumption. The powder formulation must not be ingested in its dry state.
Missed-Dose Rule If an administration is missed, it should be skipped, and the individual should resume the standard schedule with the next dose; double doses are prohibited.

Population and Duration Constraints

Use in children and adolescents (ages 0 to 18 years) is not recommended as the safety and effectiveness have not been established in this population. It is further advised that the total treatment course should generally not exceed one year.

This structure defines the dosage and context for the medication's use.

Advertisements

Recent Clinical Evidence

Evidence for Use in Peyronie's Disease

Clinical research for Peyronie's disease primarily involves Randomized Controlled Trials (RCTs) and open-label studies. These trials studied adult males, examining outcomes like changes in the size of the fibrotic plaque and stability or changes in penile curvature. Findings show patterns related to plaque stability, but results concerning the reduction of pre-existing curvature have been mixed. Inconsistent findings are reported across different studies, and one major regulatory body determined the research was insufficient to establish substantial effectiveness for this condition.

️ Evidence for Use in Scleroderma and Morphea

The research base for scleroderma and morphea includes earlier observational studies and retrospective settings. These studies focused on outcomes related to systemic imbalance, such as changes in skin thickness and pliability, and changes in measurements of physiological movement. Observations from these studies reported patterns related to these tissue changes. Because this evidence is predominantly historical, comparative data is lacking, and the data are still emerging from more modern research scenarios.

️ Long-Term Studies and Follow-Up Data

The majority of controlled research was conducted over observation periods of approximately six to twelve months. Follow-up durations were limited in the primary randomized studies, and currently, long-term effects are not fully established. Research describing extended outcomes—such as the durability of reported changes beyond one year—is insufficient.

Evidence in Specific Patient Groups (Special Populations)

The research primarily focused on general adult populations. Data for certain groups remain insufficient, meaning the evidence is limited regarding how outcomes may evolve for pediatric or pregnant populations. The available evidence has limited application to patients defined by certain comorbid conditions.

What Is Still Uncertain About the Research

Certainty remains low in several areas due to the mixed findings and inconsistency across trials. Evidence quality varies, contributing to differing regulatory conclusions internationally. The most significant gap is the insufficient information for long-term outcomes, as existing studies provide limited insight into the durability of any measured changes.

Key Studies & References

  1. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Potaba-Glenwood (FAQ)


Q: Is Potaba-Glenwood the same as the generic drug potassium aminobenzoate?

Potaba-Glenwood is the brand name for a prescription medication. Its active ingredient is Potassium para-aminobenzoate (K-PABA), which is the generic drug name. This substance is a specific synthetic salt derived from aminobenzoic acid.


Q: Does Potaba-Glenwood treat all forms of tissue hardening, or just specific diseases like Peyronie's and scleroderma?

According to official product information, this medication is approved to address conditions involving fibrosis (tissue hardening or tightening). This includes specific diseases such as scleroderma, morphea, and Peyronie's disease.


Q: What happens in the body to the potassium component of Potaba-Glenwood?

The potassium in the drug contributes to the body’s overall potassium level. Official documents note that this content makes the medication contraindicated (prohibited) for use in people with kidney disease due to a significant risk of hyperkalaemia (abnormally high blood potassium levels). For this reason, caution is required when taken with other potassium-elevating medicines.


Q: What are the known severe side effects that have been reported with Potaba-Glenwood?

The official safety profile identifies several serious adverse reactions. These include Severe Cutaneous Adverse Reactions (SCARs), such as DRESS syndrome, which involves severe skin and systemic issues. Other serious risks involve Hepatobiliary disorders (such as drug-induced liver injury) and metabolic issues like hypoglycaemia (low blood sugar).


Q: Can Potaba-Glenwood cause symptoms related to low blood sugar (hypoglycemia)?

Yes, official safety information indicates that this medication can rarely cause hypoglycaemia (low blood sugar) as a side effect. Symptoms that may indicate low blood sugar include confusion, shaking, anxiety, headache, cold sweats, and unusual weakness. These symptoms may also be harder to detect in older adults.


Q: Can a patient use Potaba-Glenwood if they are currently taking the medicine methotrexate?

The regulatory documents note a specific interaction where co-administration with Methotrexate may increase the plasma levels of Methotrexate in the body due to protein-binding displacement. Caution is required when these two medicines are used together.


Q: What information is available regarding the use of Potaba-Glenwood during pregnancy?

Use of the medicine during pregnancy is not recommended because the safety and effectiveness have not been formally established in this population. Use is generally reserved for situations where the potential benefit has been carefully assessed.


Q: Is it considered safe to take Potaba-Glenwood while breastfeeding?

Use of Potaba-Glenwood while breastfeeding is not recommended in official guidelines. It is currently unknown whether the drug passes into breast milk. Use is generally reserved for situations where the potential benefit has been carefully assessed.


Q: What information is available regarding the use of Potaba-Glenwood in older adults?

Official information indicates that older adults may be more sensitive to certain side effects. Specifically, symptoms of hypoglycaemia (low blood sugar) may be harder to detect or recognize in older individuals compared to younger adults.


Q: Does chilling the dissolved powder improve its taste, as some users claim?

Regulatory-approved patient guidance indicates that the flavor of the solution is often improved if the liquid is chilled before consumption. The powder is required to be dissolved in a full glass of water or fruit juice prior to taking.


Q: Can taking Potaba-Glenwood affect a patient's blood pressure readings?

The drug is not explicitly stated to affect blood pressure, but official documents caution about interactions with common blood pressure medicines like ACE inhibitors and ARBs. The risk of hyperkalaemia is also associated with heart rhythm changes.


Q: Is it possible to become oversensitive to the medication over time, and what are the signs?

There is a risk of Severe Cutaneous Adverse Reactions (SCARs) and hypersensitivity reactions that can develop after starting treatment. Signs that have been reported and should be noted include a severe rash, fever, muscle pain, blisters, or symptoms indicative of a liver disorder.


Q: What are the possible visual symptoms of liver disorder that a patient should watch for?

Patients are required to be monitored due to the risk of liver injury. Signs of liver issues that a patient should watch for, as noted in official patient guidance, include jaundice (yellowing of the skin or eyes) and dark urine.


Q: Is it necessary to take the medication at specific times of the day for best results?

The total daily dose must be divided and taken in four separate doses daily. However, the exact clock times are not specified in the guidelines. The key administration rule is that each dose is taken with food.


Q: Is Potaba-Glenwood intended for short-term or long-term use?

Official guidelines advise that the total course of treatment should generally not exceed one year. This defined limit places constraints on the long-term use of the medication.


Q: What does the available research say about the long-term safety of taking Potaba-Glenwood?

The majority of controlled research was conducted over observation periods of approximately six to twelve months. Official documents state that research describing extended outcomes, or the durability of reported changes beyond one year, is currently considered insufficient.


Q: Can I crush the tablet form of Potaba-Glenwood?

Regulatory-approved patient guidance states that tablets should be dissolved in water before taking them. This preparation is advised to help lessen the possibility of stomach upset.


Q: Does Potaba-Glenwood have any effects on white blood cells or platelets?

While direct effects are not detailed, official notes state that laboratory and/or medical tests, such as white blood cell counts, may be performed periodically. Official notes state that these tests may be performed periodically.


Q: What is the purpose of dissolving the tablets in water before taking them?

Patients using the tablets are advised to dissolve them in water before taking them. This preparation step is specifically designed to help lessen the possibility of stomach upset.


Q: What happens if I cannot eat normally because of nausea from the medication?

Official documentation requires that treatment be interrupted during any periods of low food intake (e.g., due to nausea). This interruption is necessary to mitigate the possible development of hypoglycaemia (low blood sugar), which can be severe.


Q: Does Potaba-Glenwood interact with non-prescription pain relievers?

The medication is known to carry an interaction risk with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes many non-prescription pain relievers. This combination requires monitoring because of the increased risk of hyperkalaemia (high blood potassium levels).

Advertisements

How should Potaba-Glenwood be stored and disposed of?

How to Store and Dispose of Potaba-Glenwood

The required storage and disposal conditions for Potaba-Glenwood (potassium para-aminobenzoate) are outlined in official regulatory documentation to maintain product integrity and ensure safe handling.

Storage Requirement Official Condition
Temperature Do not store above 25 °C (77 °F).
Protection Store in the original packaging to protect the medicine from light and moisture.
Stability Must not be used after the expiry date printed on the carton.
Child Safety Keep this medicine out of the sight and reach of children.

Any unused product or waste material must be disposed of in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Potaba-Glenwood found in:

A-Z Index: